Navigation path

Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

Naptumomab estafenatox

EU orphan designation number: EU/3/07/480   
Active ingredient: Naptumomab estafenatox
Indication: Treatment of renal cell carcinoma
Sponsor: Active Biotech AB
Scheelevägen 22, Box 724, 220 07 Lund, Sverige

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
19/09/2007 Orphan designation EMEA/OD/048/07 (2007)4326 of 14/09/2007
26/09/2011 Change of name and/or address of sponsor EMEA/OD/048/07